Ferenc Martenyi

Vice President

Cambridge, Massachusetts, United States

Professional Overview
Ferenc Martenyi is an accomplished pharmaceutical executive with over 20 years of experience in clinical development, medical affairs, and global operations. As the Vice President at QurAlis, he leverages his deep expertise in neurodegenerative diseases to drive the company's clinical programs and strategic initiatives.

Experience Summary

Current Role
As the Vice President at QurAlis, Mr. Martenyi is responsible for overseeing the company's clinical development pipeline, including the advancement of novel therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative disorders. He plays a pivotal role in aligning the company's clinical strategy with its overall business objectives and fostering collaborative partnerships to accelerate the delivery of innovative treatments to patients.

Career Progression
Prior to joining QurAlis, Mr. Martenyi held several senior-level positions at leading pharmaceutical companies. As the Vice President and Head of Clinical Development at Prothena Corporation plc, he successfully led the company's late-stage clinical trials and regulatory submissions for a novel Parkinson's disease therapy. Earlier in his career, he served as a Senior Medical Director at Aptinyx Inc. and Takeda Pharmaceuticals, where he contributed to the advancement of their neuroscience drug pipelines. Additionally, Mr. Martenyi has held global development leadership roles at F. Hoffmann-La Roche and Eli Lilly and Company, further expanding his expertise in the central nervous system (CNS) therapeutic area.

Academic Background
Mr. Martenyi holds a medical degree from Semmelweis University, School of Medicine, where he also completed his academic positions prior to transitioning to the pharmaceutical industry.

Areas of Expertise

• Clinical development strategy and execution in neurodegenerative diseases

• Medical affairs and global operations management

• Expertise in CNS therapeutic area, with a focus on ALS, Parkinson's disease, and Alzheimer's disease

• Proven track record of leading cross-functional teams and driving successful regulatory submissions

• Extensive experience in fostering industry partnerships and collaborations

Professional Impact
During his tenure at Prothena, Mr. Martenyi played a pivotal role in the successful completion of a Phase 2 clinical trial for a Parkinson's disease therapy, which led to a significant milestone payment and strengthened the company's pipeline. Additionally, his leadership in the development and regulatory approval of several CNS-focused therapies at Takeda and Eli Lilly has contributed to improved treatment options for patients with neurological disorders.

Conclusion
With his extensive experience in the pharmaceutical industry and deep expertise in neurodegenerative diseases, Ferenc Martenyi is poised to drive the clinical development and strategic growth of QurAlis. His proven track record of leading successful drug development programs and fostering industry partnerships makes him a valuable asset in the company's mission to deliver innovative therapies to patients in need.